Biofrontera (BFRI) Liabilities and Shareholders Equity (2020 - 2025)

Biofrontera's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $28.6 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 29.24% year-over-year to $28.6 million in Q4 2025; TTM through Dec 2025 was $80.7 million, a 6.98% decrease from a year earlier, with the FY2025 full-year figure at $28.6 million, up 29.24% from the prior year.
• Liabilities and Shareholders Equity improved to $28.6 million in Q4 2025 per BFRI's latest filing, from $15.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $55.1 million in Q3 2022 and bottomed at $8000.0 in Q4 2021.
• The 5-year median for Liabilities and Shareholders Equity is $24.6 million (2024), against an average of $29.2 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 99.97% in 2021 and jumped 635950.0% in 2022, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $8000.0 in 2021, then soared by 635950.0% to $50.9 million in 2022, then sank by 45.11% to $27.9 million in 2023, then declined by 20.88% to $22.1 million in 2024, then grew by 29.24% to $28.6 million in 2025.
• Per Business Quant, the three latest BFRI Liabilities and Shareholders Equity figures stand at $28.6 million (Q4 2025), $15.4 million (Q3 2025), and $20.1 million (Q2 2025).